Help your patients with Parkinson’s disease (PD)
Get back on
with

KYNMOBItm

KYNMOBI Power On Logo
(apomorphine HCl)
sublingual film
The first and only sublingual treatment for OFF episodes1,2

INDICATION
KYNMOBITM (apomorphine hydrochloride) sublingual film is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of "off" episodes in patients with Parkinson’s disease.

KYNMOBI sublingual film is a blue to green rectangular film with a white printed number identifying the strength (e.g., “10” is 10 mg).
KYNMOBI sublingual film is a blue to green rectangular film with a white printed number identifying the strength (e.g., “10” is 10 mg).

 

References: 1. Kynmobi. Prescribing information. Sunovion Pharmaceuticals Inc; May 2020. 2. Olanow CW, Factor SA, Espay AJ, et al; for the CTH-300 Study Investigators. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomized, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19[2]:135-144.

Top

Thank you for registering at KYNMOBI!

We look forward to telling you more about KYNMOBI, a new medication to treat OFF episodes associated with Parkinson's disease, as it becomes available.

You have been successfully unsubscribed.

Please allow 7-10 days to process your request.